{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Maridebart+Cafraglutide",
    "query": {
      "intervention": "Maridebart Cafraglutide"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 23,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Maridebart+Cafraglutide&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-02T04:51:49.428Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05056246",
      "title": "Study of AMG 133 Administered Subcutaneously in Healthy Japanese and Caucasian Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Participants"
      ],
      "interventions": [
        {
          "name": "AMG 133",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 34,
      "start_date": "2021-09-10",
      "completion_date": "2022-04-08",
      "has_results": true,
      "last_update_posted_date": "2025-02-25",
      "last_synced_at": "2026-09-02T04:51:49.428Z",
      "location_count": 1,
      "location_summary": "Cypress, California",
      "locations": [
        {
          "city": "Cypress",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05056246"
    },
    {
      "nct_id": "NCT07429032",
      "title": "The Effect of AMG 133 on Gastric Emptying",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Overweight or Obesity"
      ],
      "interventions": [
        {
          "name": "AMG 133",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Acetaminophen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 57,
      "start_date": "2025-04-17",
      "completion_date": "2025-11-26",
      "has_results": false,
      "last_update_posted_date": "2026-02-24",
      "last_synced_at": "2026-09-02T04:51:49.428Z",
      "location_count": 1,
      "location_summary": "Daytona Beach, Florida",
      "locations": [
        {
          "city": "Daytona Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07429032"
    },
    {
      "nct_id": "NCT07037459",
      "title": "Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Heart Failure With Preserved Ejection Fraction",
        "Heart Failure With Mildly Reduced Ejection Fraction",
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Maridebart cafraglutide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 5056,
      "start_date": "2025-06-25",
      "completion_date": "2030-09-29",
      "has_results": false,
      "last_update_posted_date": "2026-07-02",
      "last_synced_at": "2026-09-02T04:51:49.428Z",
      "location_count": 111,
      "location_summary": "Birmingham, Alabama • Dothan, Alabama • Fairhope, Alabama + 99 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Fairhope",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07037459"
    },
    {
      "nct_id": "NCT07575399",
      "title": "Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Obesity or Overweight"
      ],
      "interventions": [
        {
          "name": "Maridebart Cafraglutide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 300,
      "start_date": "2026-05-11",
      "completion_date": "2028-02-28",
      "has_results": false,
      "last_update_posted_date": "2026-08-27",
      "last_synced_at": "2026-09-02T04:51:49.428Z",
      "location_count": 44,
      "location_summary": "Pelham, Alabama • Chandler, Arizona • Sun City, Arizona + 38 more",
      "locations": [
        {
          "city": "Pelham",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Palm Springs",
          "state": "California"
        },
        {
          "city": "Rialto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07575399"
    },
    {
      "nct_id": "NCT07313761",
      "title": "A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Overweight and Obesity"
      ],
      "interventions": [
        {
          "name": "Maridebart Cafraglutide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 349,
      "start_date": "2025-12-15",
      "completion_date": "2026-07-02",
      "has_results": false,
      "last_update_posted_date": "2026-08-07",
      "last_synced_at": "2026-09-02T04:51:49.428Z",
      "location_count": 4,
      "location_summary": "Anaheim, California • Los Alamitos, California • Miami, Florida + 1 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Los Alamitos",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07313761"
    },
    {
      "nct_id": "NCT04478708",
      "title": "Single and Multiple Ascending Dose Study of AMG 133 in Participants With Obesity",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Obesity"
      ],
      "interventions": [
        {
          "name": "maridebart cafraglutide",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 110,
      "start_date": "2020-08-07",
      "completion_date": "2022-11-18",
      "has_results": true,
      "last_update_posted_date": "2025-12-10",
      "last_synced_at": "2026-09-02T04:51:49.428Z",
      "location_count": 3,
      "location_summary": "Anaheim, California • Tustin, California • Miami, Florida",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Tustin",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04478708"
    },
    {
      "nct_id": "NCT07523711",
      "title": "Effect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and Processed in the Body in Postmenopausal Female Participants Living With Overweight or Obesity",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Overweight",
        "Obesity"
      ],
      "interventions": [
        {
          "name": "COC",
          "type": "DRUG"
        },
        {
          "name": "Maridebart Cafraglutide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": "65 Years",
        "sex": "FEMALE",
        "summary": "45 Years to 65 Years · Female only"
      },
      "enrollment_count": 49,
      "start_date": "2026-04-09",
      "completion_date": "2026-11-18",
      "has_results": false,
      "last_update_posted_date": "2026-07-20",
      "last_synced_at": "2026-09-02T04:51:49.428Z",
      "location_count": 2,
      "location_summary": "Dallas, Texas • Madison, Wisconsin",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07523711"
    },
    {
      "nct_id": "NCT07225686",
      "title": "Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Obesity",
        "Obstructive Sleep Apnea"
      ],
      "interventions": [
        {
          "name": "Maridebart cafraglutide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 250,
      "start_date": "2025-12-19",
      "completion_date": "2028-09-13",
      "has_results": false,
      "last_update_posted_date": "2026-08-04",
      "last_synced_at": "2026-09-02T04:51:49.428Z",
      "location_count": 13,
      "location_summary": "Northridge, California • Rolling Hills Estates, California • Brandon, Florida + 10 more",
      "locations": [
        {
          "city": "Northridge",
          "state": "California"
        },
        {
          "city": "Rolling Hills Estates",
          "state": "California"
        },
        {
          "city": "Brandon",
          "state": "Florida"
        },
        {
          "city": "Palmetto Bay",
          "state": "Florida"
        },
        {
          "city": "Pompano Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07225686"
    },
    {
      "nct_id": "NCT07226778",
      "title": "Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous (SC) Presentations",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Overweight",
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Maridebart Cafraglutide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 348,
      "start_date": "2025-10-10",
      "completion_date": "2026-05-28",
      "has_results": false,
      "last_update_posted_date": "2026-06-17",
      "last_synced_at": "2026-09-02T04:51:49.428Z",
      "location_count": 4,
      "location_summary": "Anaheim, California • Daytona Beach, Florida • Dallas, Texas + 1 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Daytona Beach",
          "state": "Florida"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07226778"
    },
    {
      "nct_id": "NCT06858878",
      "title": "Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight"
      ],
      "interventions": [
        {
          "name": "Maridebart cafraglutide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 1105,
      "start_date": "2025-03-17",
      "completion_date": "2027-04-16",
      "has_results": false,
      "last_update_posted_date": "2025-12-31",
      "last_synced_at": "2026-09-02T04:51:49.428Z",
      "location_count": 59,
      "location_summary": "Mobile, Alabama • Gilbert, Arizona • Mesa, Arizona + 53 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Canoga Park",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06858878"
    }
  ]
}